Tag: Alnylam Pharmaceuticals

November 24, 2019

5 Top NASDAQ Biotech and Pharma Stocks: Fulcrum Climbs 73 Percent

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
November 20, 2019

Alnylam Gets FDA Nod for Rare Disease Drug

The FDA's approval of Alnylam's Gilvaari treatment is the first approval of its kind for acute hepatic porphyria.
August 13, 2019

Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ironwood Pharmaceuticals (NASDAQ:IRWD) has announced a US GI disease education and promotional agreement for Alnylam’s givosiran...
January 21, 2019

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an...
November 25, 2018

What is In-licensing?

In-licensing may be pharma’s preferred mode of business development these days. Should that impact your investment strategy?
October 15, 2018

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA),...
September 14, 2018

Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran

Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today publication of data from exploratory cardiac assessments in the APOLLO...